FDA Approves XEOMIN — Merz Pharmaceuticals, LLC

On July 30, 2010, Merz Pharmaceuticals, LLC received FDA approval for XEOMIN (incobotulinumtoxin A), signaling a new entrant in the botulinum toxin type A market that is poised to compete with high-profile rivals by offering the advantage of a purified botulinum complex without preservatives. The approval carries significant industry implications as it challenges competitor pricing models and offers physicians a unique sterile-dose product better suited for the multi-use vial market.